# US 10,765,687 B2 · Methods and compounds to inhibit enveloped virus release

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,687 B2
- Document ID: US10765687B2
- Status: Granted
- Kind: B2
- Application number: 16/361,556
- Filed: 2019-03-22
- Published: 2019-07-11
- Granted: 2020-09-08
- Earliest claimed: 2012-12-21
- Assignees: Northwestern University; The Research Foundation for The State University of New York
- Applicants: Northwestern University; The Research Foundation for the State of University of New York
- Inventors: Jonathan Leis; Carol Carter
- Web page: https://patentgrep.com/patent/US10765687B2

## CPC

- A61K 31/65: Tetracyclines
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/415: 1,2-Diazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.

## Claims

### Claim 1

A method of treating an infection by an enveloped virus in a patient, the method consisting of administering to the patient a pharmaceutical composition consisting of a compound of a formula:

### Claim 2 (depends on 1)

The method of claim 1, wherein the enveloped virus is selected from the group consisting of Lassa fever virus, lymphocytic choriomeningitis virus, Ebola virus, Marberg virus, hepatitis B virus, Herpes simplex virus, type 1, Herpes simplex virus, type 2, cytomegalovirus, Simian virus, type 5, Mumps virus, avian sarcoma leucosis virus, human immunodeficiency virus, type 1, human T-lymphotrophic virus, type 1, equine infectious anemia virus, vesicular stomatitis virus, rabies virus, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound has antiviral activity against the enveloped virus selected from (i) inhibiting formation of an associative complex, (ii) disrupting formation of an associative complex, and (iii) both of (i) and (ii), wherein the associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.

### Claim 4 (depends on 3)

The method of claim 3, wherein the L-domain motif comprises at least one of a PY-motif or a PTAP-motif.